D. E. Shaw & Co. Inc. Acquires 524,802 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

D. E. Shaw & Co. Inc. grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 171.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 831,414 shares of the biopharmaceutical company's stock after buying an additional 524,802 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.65% of Halozyme Therapeutics worth $39,750,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Smartleaf Asset Management LLC grew its stake in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the last quarter. Louisiana State Employees Retirement System lifted its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock valued at $1,688,000 after buying an additional 200 shares during the period. Baird Financial Group Inc. lifted its holdings in Halozyme Therapeutics by 2.0% in the fourth quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock valued at $532,000 after buying an additional 221 shares during the period. CreativeOne Wealth LLC lifted its holdings in Halozyme Therapeutics by 1.6% in the fourth quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock valued at $879,000 after buying an additional 294 shares during the period. Finally, State of New Jersey Common Pension Fund D lifted its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock valued at $2,279,000 after buying an additional 302 shares during the period. Institutional investors own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now directly owns 185,453 shares of the company's stock, valued at $10,765,546.65. This trade represents a 5.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now directly owns 33,108 shares of the company's stock, valued at $2,120,567.40. This trade represents a 1.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,697 shares of company stock valued at $1,276,552. Insiders own 2.40% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a report on Tuesday. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $73.00 to $62.00 in a report on Wednesday. Finally, JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock traded up $2.99 on Friday, hitting $51.94. 2,050,803 shares of the company traded hands, compared to its average volume of 1,592,278. The firm's 50-day simple moving average is $60.88 and its 200 day simple moving average is $55.89. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company has a market cap of $6.40 billion, a P/E ratio of 15.14, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. During the same quarter last year, the company posted $0.79 EPS. The business's quarterly revenue was up 35.2% on a year-over-year basis. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.